The U.S. Small Business Administration issued a “green light” or “go forth” letter inviting Hercules Capital to finalize its application process to obtain a license to form and operate a third small business investment company subsidiary.
Hercules Capital entered into a $100 million debt financing agreement with G1 Therapeutics, a clinical-stage oncology company. G1 plans to use the proceeds to fund commercialization and further development of trilaciclib.
Hercules Capital has replaced its existing $200 million credit facility with MUFG Union Bank with a new $400 million credit facility.
ChemoCentryx has secured a credit facility of up to $100 million provided by Hercules Capital.
Urovant Sciences has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma, a global Japanese pharmaceutical company.
Axovant Gene Therapies amended its loan and security agreement with Hercules Capital.
Hercules Capital has appointed Scott Bluestein as its chief executive officer and president, effective immediately.
Antares Pharma amended its credit facility with Hercules Capital, to increase the available debt capital by $25 million for a term loan of up to $50 million.
Hercules Capital promoted R. Bryan Jadot to head of Life Sciences Venture Lending and Steve Kuo to head of Technology Venture Lending.
Tricida has entered into an amendment to its existing debt facility with Hercules Capital. The amendment increases the total amount available under the debt facility to up to $200 million and extends the maturity of the loans thereunder. Tricida originally entered into a $100 million debt facility with Hercules Capital in February 2018.